Conexeu Launches Preclinical WFIRM Trial for B.R.E.A.S.T.™ 3D-Printed Scaffold
MDXG•Conexeu Sciences began trading May 21 with 25.27 million shares outstanding and launched a preclinical program at WFIRM to test its B.R.E.A.S.T.™ 3D-printed scaffold via the iTOPS bioprinting system. The CXU™ platform holds issued patents in the US, EU, Japan and Australia and targets a predicate-based 510(k) in early 2027.
1. Nasdaq Listing and Share Structure
Conexeu began trading on Nasdaq May 21, 2026, issuing 25.27 million shares with 35.24 million shares on a fully diluted basis. H.C. Wainwright & Co. served as exclusive financial advisor for the listing.
2. WFIRM Preclinical Development
On May 27 Conexeu initiated a preclinical program at Wake Forest Institute for Regenerative Medicine using the Integrated Tissue-Organ Printing System to evaluate durability under physiological conditions, host-tissue integration and scaffold resorbability of its B.R.E.A.S.T.™ 3D-printed matrix.
3. CXU™ Platform and Future Plans
The CXU™ extracellular-matrix platform underpins multiple pipeline candidates, including Ten Minute Tissue™, and holds issued patents in the US, EU, Japan and Australia with no royalty obligations. Management is pursuing a predicate-based 510(k) filing in early 2027 and plans to expand into wound care, dental, contouring and veterinary applications.
